12,404
Total Claims
$1.8M
Drug Cost
1,314
Beneficiaries
$1,346
Cost/Patient
Peer Comparison vs. 4,479 Interventional Cardiology providers
+28%
Cost per patient vs peers
$1,346 vs $1,054 avg
+27%
Brand preference vs peers
16.7% vs 13.1% avg
Brand vs Generic
83% generic
Brand: 2,066 claims · $1.6M
Generic: 10,338 claims · $219K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 612 | $500K |
| Sacubitril/Valsartan | 262 | $274K |
| Dapagliflozin Propanediol | 268 | $208K |
| Rivaroxaban | 149 | $141K |
| Evolocumab | 184 | $140K |
| Empagliflozin | 107 | $92K |
| Ticagrelor | 134 | $91K |
| Ranolazine | 399 | $46K |
| Alirocumab | 53 | $34K |
| Semaglutide | 24 | $24K |
| Pitavastatin Calcium | 24 | $14K |
| Metoprolol Succinate | 927 | $13K |
| Rosuvastatin Calcium | 510 | $12K |
| Atorvastatin Calcium | 942 | $11K |
| Clopidogrel Bisulfate | 854 | $11K |
Prescribing Profile
Patient Profile
72
Avg Age
50%
Female
1.56
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About